Chong Kun Dang Pharmaceutical Corp.

Symbol: 185750.KS

KSC

101200

KRW

Market price today

  • 6.4696

    P/E Ratio

  • -0.0542

    PEG Ratio

  • 1.29T

    MRK Cap

  • 0.01%

    DIV Yield

Chong Kun Dang Pharmaceutical Corp. (185750-KS) Financial Statements

On the chart you can see the default numbers in dynamics for Chong Kun Dang Pharmaceutical Corp. (185750.KS). Companys revenue shows the average of 979923.666 M which is 0.555 % gowth. The average gross profit for the whole period is 389538.279 M which is 0.671 %. The average gross profit ratio is 0.421 %. The net income growth for the company last year performance is 1.625 % which equals 1.459 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Chong Kun Dang Pharmaceutical Corp., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.247. In the realm of current assets, 185750.KS clocks in at 946571.861 in the reporting currency. A significant portion of these assets, precisely 365065.296, is held in cash and short-term investments. This segment shows a change of 1.342% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 67179.09, if any, in the reporting currency. This indicates a difference of 1107.072% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 30000 in the reporting currency. This figure signifies a year_over_year change of -1.000%. Shareholder value, as depicted by the total shareholder equity, is valued at 815694.495 in the reporting currency. The year over year change in this aspect is 0.311%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 311468.61, with an inventory valuation of 261431.89, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 52527.15. Account payables and short-term debt are 183938.77 and 184767.37, respectively. The total debt is 219763.88, with a net debt of 117.53. Other current liabilities amount to 134996.55, adding to the total liabilities of 586793.27. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013

balance-sheet.row.cash-and-short-term-investments

977306.91365065.3155861.2187332.6
161855.4
92373.2
45948.7
45471.2
21720.8
12853
51350.8
16276.6

balance-sheet.row.short-term-investments

234574.58145418.938444.355519.9
38196.3
15450.7
0
0
0
0
2580
3120

balance-sheet.row.net-receivables

1166084.87311468.6287306.6234703.7
226958.6
205590.1
216791.7
216913
218776
185529.6
171848.2
167870.6

balance-sheet.row.inventory

1101639.04261431.9270081.5224722.9
185565.2
148453.7
127590.7
104338.7
98260.5
89982.7
75236.2
71155.4

balance-sheet.row.other-current-assets

9554.788606.1365.520387.9
25734.9
24718
0
181.3
0
0
0
0

balance-sheet.row.total-current-assets

3254585.6946571.9713614.8667147.2
600114.1
471135
390331.1
366904.2
338757.3
288365.4
298435.2
255302.6

balance-sheet.row.property-plant-equipment-net

1263852.99319787.1310697.4298909.7
274650.3
263086.3
254109.3
252376.7
244675.5
228026.5
215240.3
214686.3

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

176043.6452527.12695320805.5
19032.5
15915
15375.9
14333.8
14858.3
15843.7
16073.6
17833.6

balance-sheet.row.goodwill-and-intangible-assets

176043.6452527.12695320805.5
19032.5
15915
15375.9
14333.8
14858.3
15843.7
16073.6
17833.6

balance-sheet.row.long-term-investments

110109.367179.15565.5-22146.7
-11632.1
9641.6
0
0
0
0
14487.8
5937

balance-sheet.row.tax-assets

35440.2714213.26208.62350.3
63996.8
41402.7
0
0
0
0
26690.5
25350.3

balance-sheet.row.other-non-current-assets

186897.572150.161843.579634.1
171.5
171.5
51678.6
43590.6
43407.7
44051.1
2826.6
2841.3

balance-sheet.row.total-non-current-assets

1772343.77455856.6411268379552.9
346219
330217.1
321163.8
310301.1
302941.5
287921.3
275318.9
266648.6

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

5026929.371402428.41124882.81046700.1
946333.1
801352.1
711494.9
677205.3
641698.9
576286.7
573754.1
521951.2

balance-sheet.row.account-payables

677227.23183938.8145436.3129327.4
144120.1
101969.5
68592
71181.4
71204.3
49529.3
40051.2
34407.2

balance-sheet.row.short-term-debt

615980.74184767.4124445.5102091.4
78632.1
92213
58578
81100
84567
53967
80600
63567

balance-sheet.row.tax-payables

130003.7843938.229026.418701.1
29209.6
19461
21695.8
24172.2
20840.4
13544.6
10136.6
3722.1

balance-sheet.row.long-term-debt-total

301223.1330000111292.6134962.3
57509.2
25845.3
45892.1
21358.2
40000
70600
43967
61000

Deferred Revenue Non Current

14490.661484.86438.35982
13290.9
21309
0
0
0
0
0
25019.9

balance-sheet.row.deferred-tax-liabilities-non-current

21900.45---
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

286154.11134996.698922.320691.5
20802.7
19255
55643.4
0
34830.5
34401.9
30529.7
29156.7

balance-sheet.row.total-non-current-liabilities

395681.8575327.4129380.9160660.6
74119.5
49329.9
76086.1
49862.7
76006.2
110282.8
80988.9
92974.4

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

31147.984996.51694.23470.5
5161.5
7014.6
0
0
0
0
0
0

balance-sheet.row.total-liab

2153650.5586793.3503594480890.4
394740.3
326398.9
280595.3
273910.4
287448.5
261725.6
242306.4
223827.5

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

125684.6431421.229970.128565.2
27214.2
25925.7
24698.1
23522.6
23522.6
23522.6
23522.6
23522.6

balance-sheet.row.retained-earnings

1554612.31218102.4376370.8302106.6
272194.1
184629
142550.9
106031.1
58888.9
19533.3
34568.9
3456.9

balance-sheet.row.accumulated-other-comprehensive-income-loss

1404661.23350829.8276706.4250156.9
173748.2
130262.5
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

-210144.4215341.1-60654.3-14818.7
78270.3
132702.9
261476.2
272161.1
271838.9
271505.1
273356.1
271144.2

balance-sheet.row.total-stockholders-equity

2874813.78815694.5622393.1566010
551426.8
473520.1
428725.1
401714.9
354250.4
314561.1
331447.7
298123.7

balance-sheet.row.total-liabilities-and-stockholders-equity

5026929.371402428.41124882.81046700.1
946333.1
801352.1
711494.9
677205.3
641698.9
576286.7
573754.1
521951.2

balance-sheet.row.minority-interest

-1534.92-59.3-1104.3-200.3
166
1433.1
2174.4
1580.1
0
0
0
0

balance-sheet.row.total-equity

2873278.86815635.2621288.8565809.6
551592.8
474953.2
430899.6
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

5026929.37---
-
-
-
-
-
-
-
-

Total Investments

344683.8821259844009.833373.2
26564.2
25092.3
24831.7
17839.3
18513.8
15547.7
17067.8
9057

balance-sheet.row.total-debt

922200.38219763.9235738.1237053.8
136141.3
118058.3
104470.1
102458.2
124567
124567
124567
124567

balance-sheet.row.net-debt

179468.05117.5118321.2105241.1
12482.3
41135.7
58521.4
56987
102846.2
111714
75796.2
111410.4

Cash Flow Statement

The financial landscape of Chong Kun Dang Pharmaceutical Corp. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -1.000. The company recently extended its share capital by issuing -3335.33, marking a difference of 4.842 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to -171312903890.000 in the reporting currency. This is a shift of 1.620 from the previous year. In the same period, the company recorded 36942.22, 39.75, and -22714.6, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -11608.53 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as -16.53, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013

cash-flows.row.net-income

213740.93212521.279977.842356.5
90404.9
52975.3
41704.4
53728.3
40946.1
-6772.7
35153.7
4417

cash-flows.row.depreciation-and-amortization

37007.9636942.233597.727481.9
23785.6
23052.4
21218
21985.3
23933.6
22677.3
20548
3280.4

cash-flows.row.deferred-income-tax

0000
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0000
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

29681.8429681.8-77299.3-71568.7
-51482.9
-21554.3
-41438.1
-21599.2
-36176.6
-26701.6
-5963
426.3

cash-flows.row.account-receivables

-29559.69-29559.7-51435.9-6926
-21894
10832.8
0
0
0
0
0
0

cash-flows.row.inventory

-5980.26-5980.3-54466.2-53770.6
-46240.1
-48845.1
-30802.9
-19587.6
-17639.5
-19504.8
-5926.8
3998.9

cash-flows.row.account-payables

38583.7838583.815824.5-15597.8
42358
33400.7
0
0
0
0
0
0

cash-flows.row.other-working-capital

26638.012663812778.24725.7
-25706.8
-16942.8
-10635.1
-2011.6
-18537.1
-7196.8
-36.2
-3572.5

cash-flows.row.other-non-cash-items

37729.1739014.731458.414634.2
41616.1
22817.2
21143.4
27558.5
29083
18069
14852
1836

cash-flows.row.net-cash-provided-by-operating-activities

318159.91000
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-68806.05-68806-53064.7-51844.4
-36817.7
-24861.9
-24640.2
-21322.2
-39439.5
-35673.2
-21324.3
-2118.9

cash-flows.row.acquisitions-net

20636.77451.6142.1-3448.7
-4109.9
-2690.6
0
71.6
-3076.4
-2096.6
-2499.5
0

cash-flows.row.purchases-of-investments

-192468.23-192468.2-57181.1-61266.4
-59956.7
-17051.7
-6204.2
-20241
-1147.7
-1663.7
-7992.7
-447.7

cash-flows.row.sales-maturities-of-investments

89470.048947044375.621934.7
32516.4
1800
0
17031.7
-1205.9
3096
3440
0

cash-flows.row.other-investing-activites

-20145.4339.8347.83815.5
4446.8
3077.4
509.4
579.6
1471.6
407.6
2588.1
175.1

cash-flows.row.net-cash-used-for-investing-activites

-171312.9-171312.9-65380.3-90809.3
-63921.1
-39726.7
-30335
-23880.3
-43397.8
-35929.9
-25788.5
-2391.4

cash-flows.row.debt-repayment

-44714.6-22714.6-0.3-896.2
-61966.1
-11831.3
-75035.6
-43467
-77500
-10000
-1600
0

cash-flows.row.common-stock-issued

0-3335.300
0
0
1358.2
0
0
0
0
0

cash-flows.row.common-stock-repurchased

-6024.99-6025-1888.4-1935.3
-2078
-442.9
-6950.2
0
0
0
0
-383.6

cash-flows.row.dividends-paid

0-11608.5-11238.8-10808.3
-9277.1
-8839
-8463.3
-8463.3
-5642.2
-7523
-2821.1
0

cash-flows.row.other-financing-activites

18648.14-16.5-3212.498778.7
80390
14525.1
77353.9
17198.9
77500
10000
1600
0

cash-flows.row.net-cash-used-provided-by-financing-activities

-43699.98-43700-16339.885138.9
7068.8
-6588.1
-11737
-34731.5
-5642.2
-7523
-2821.1
-383.6

cash-flows.row.effect-of-forex-changes-on-cash

-917.57-917.6-410.1920.1
-734.9
-1.9
-78.3
689.3
121.8
263
-366.8
-17.2

cash-flows.row.net-change-in-cash

102229.45102229.4-14395.88153.6
46736.6
30973.8
477.5
23750.4
8867.9
-35917.9
35614.2
7167.4

cash-flows.row.cash-at-end-of-period

742732.33219646.3117416.9131812.7
123659.1
76922.5
45948.7
45471.2
21720.8
12853
48770.8
13156.6

cash-flows.row.cash-at-beginning-of-period

640502.88117416.9131812.7123659.1
76922.5
45948.7
45471.2
21720.8
12853
48770.8
13156.6
5989.1

cash-flows.row.operating-cash-flow

318159.91318159.967734.512903.9
104323.7
77290.6
42627.8
81672.8
57786.1
7272
64590.7
9959.7

cash-flows.row.capital-expenditure

-68806.05-68806-53064.7-51844.4
-36817.7
-24861.9
-24640.2
-21322.2
-39439.5
-35673.2
-21324.3
-2118.9

cash-flows.row.free-cash-flow

249353.86249353.914669.8-38940.5
67506
52428.7
17987.6
60350.7
18346.7
-28401.2
43266.4
7840.9

Income Statement Row

Chong Kun Dang Pharmaceutical Corp.'s revenue saw a change of 0.122% compared with the previous period. The gross profit of 185750.KS is reported to be 655344.55. The company's operating expenses are 408657.61, showing a change of -5.564% from the last year. The expenses for depreciation and amortization are 36942.22, which is a 0.058% change from the last accounting period. Operating expenses are reported to be 408657.61, which shows a -5.564% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 1.244% year-over-year growth. The operating income is 246686.94, which shows a 1.245% change when compared to the previous year. The change in the net income is 1.625%. The net income for the last year was 212521.17.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013

income-statement-row.row.total-revenue

1657673.311669404.41488344.71343559.4
1303005.5
1079337.7
956218.9
884362.8
831985.5
592493.5
544129.8
86318.2

income-statement-row.row.cost-of-revenue

779200.121014059.9945705.3847741.1
813865.7
675059.1
575815.6
524706.5
497098.9
296312.1
263788.5
40086.5

income-statement-row.row.gross-profit

878473.19655344.5542639.4495818.3
489139.8
404278.6
380403.3
359656.3
334886.6
296181.3
280341.2
46231.6

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

104406.15---
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

199875.81---
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

80977.59---
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

-716317.4-11694.4139957.4135069
127170.6
132350.1
-3984.2
811.8
2302.2
-21793.2
-687.7
-382.6

income-statement-row.row.operating-expenses

249710.32408657.6432733.3401059.6
365203.9
329702.9
304663.4
281891.4
273637.1
253476.2
226411
38692.7

income-statement-row.row.cost-and-expenses

1222350.411422717.51378438.71248800.7
1179069.6
1004762
880479
806597.8
770736
549788.4
490199.5
78779.2

income-statement-row.row.interest-income

4775.615789.32139716.2
1282.7
854.5
584.7
609.5
144
649.5
942.4
60.3

income-statement-row.row.interest-expense

7001.1292716846.94029.9
3870.9
3150.5
2712.2
3509.9
4171.3
4352.7
5367.1
950.6

income-statement-row.row.selling-and-marketing-expenses

80977.59---
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

1.88-5283.9-12741-14164.8
-2096.9
-2754.4
-7399.5
-3165.8
-4461.8
-27567.4
-5448.1
-1531.6

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

-716317.4-11694.4139957.4135069
127170.6
132350.1
-3984.2
811.8
2302.2
-21793.2
-687.7
-382.6

income-statement-row.row.total-operating-expenses

1.88-5283.9-12741-14164.8
-2096.9
-2754.4
-7399.5
-3165.8
-4461.8
-27567.4
-5448.1
-1531.6

income-statement-row.row.interest-expense

7001.1292716846.94029.9
3870.9
3150.5
2712.2
3509.9
4171.3
4352.7
5367.1
950.6

income-statement-row.row.depreciation-and-amortization

202519.1236942.234919.318187.3
26502.5
25946.8
21218
21985.3
23933.6
22677.3
20548
3280.4

income-statement-row.row.ebitda-caps

444402.06---
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

241882.93246686.9109906.194758.7
123935.9
74575.6
75739.9
77765
61249.5
42705.1
53930.2
7539

income-statement-row.row.income-before-tax

241884.8224140397165.180593.9
121839
71821.2
68340.3
74599.2
56787.7
15137.6
48482.1
6007.4

income-statement-row.row.income-tax-expense

39271.8927995.717187.338237.4
31434.1
18845.9
26635.9
20870.9
15841.6
21910.4
13328.4
1590.4

income-statement-row.row.net-income

201766.15212521.280953.442720.4
91632.8
53881.6
42398.5
53807.2
40946.1
-6772.7
35153.7
4417

Frequently Asked Question

What is Chong Kun Dang Pharmaceutical Corp. (185750.KS) total assets?

Chong Kun Dang Pharmaceutical Corp. (185750.KS) total assets is 1402428435512.000.

What is enterprise annual revenue?

The annual revenue is 858061047502.000.

What is firm profit margin?

Firm profit margin is 0.530.

What is company free cash flow?

The free cash flow is 19599.181.

What is enterprise net profit margin?

The net profit margin is 0.122.

What is firm total revenue?

The total revenue is 0.146.

What is Chong Kun Dang Pharmaceutical Corp. (185750.KS) net profit (net income)?

The net profit (net income) is 212521171440.000.

What is firm total debt?

The total debt is 219763880100.000.

What is operating expences number?

The operating expences are 408657610015.000.

What is company cash figure?

Enretprise cash is 219646348416.000.